MedCity News eNewsletter

Cold Genesys gets $13.6M Series A for oncolytic virus to treat bladder cancer; recycles assets from defunct biotech

Cold Genesys, a sort of latter-day spinoff of the once-promising cancer vaccine maker Cell Genesys, has an engineered oncolytic virus that shows promise in treating a dangerous form of bladder cancer.┬áThe Newport Beach, California company just received $13.6 million from Hong Kong-based investment fund Ally Bridge Group. It has rejiggered an adenovirus that typically causes […]